ICON has developed a lab logistics program to reduce costs
Q: How much of clinical trial lab budgets are spent on shipping and handling specimens?
A: Logistics typically consume up to 40 percent of lab budgets, and sometimes reach 50 percent, depending on the study. Logistics costs often end up far higher than initially projected. It is a much bigger problem than many trial managers realize.
Q: Why are lab logistic costs so high and hard to control?
The courier budgets are developed using assumptions regarding 100s and even 1000s of individual shipments. A deviation from any of these assumptions with an individual shipment will normally have minimal impact on the budget.
If that deviation continues to occur on a consistent basis over the course of a 3 or 4 year study, it can change from having minimal to significant impact on the budget. Using traditional means of logistics management this deviation will only be noticed late on into the study. At that point it, even if it’s possible to correct, the additional costs associated with that deviation will have already been incurred.
Q: How can lab logistics budget be managed more effectively?
A: The first step is to ensure that an appropriate logistics budget is created. ICON has amassed several years of independently audited logistics data, which is used to model predictive transportation. Secondly, having real-time visibility of how the lab logistics budget is being spent, and specifically identifying opportunities for cost savings on a daily basis, allows ICON to control every aspect of the logistics budget. A team of logistics and site support staff monitor this closely to drive budget compliance.
Q: Should the cheapest couriers always be used?
Price is not the only or even the most important factor in choosing a courier. Couriers also must be able to meet all technical and regulatory requirements for shipping study specimens. These include keeping packages within specified temperature ranges and timeframes to ensure specimens arrive intact and on time, documenting chain of custody, and expediting customs when international borders are crossed. Reliability in meeting schedules in specific locations is also critical. ICON’s extensive experience in managing couriers is needed to ensure all study needs are met while favorable rates are achieved.
Q: How can shipping practices at clinical sites be improved?
A: Controlling shipping practices at dozens or hundreds of clinical sites is challenging to say the least. Realistically, it requires real-time data feeds on when and how many packing supplies are ordered, and when specimen packages are shipped – something ICON is highly capable of doing. These numbers can then be compared with a pre-determined budget. Sites that are shipping more often or ordering more supplies than the budget allows can be contacted to determine why, and preventive action put in place to avoid re-occurrence.
Q: That sounds complicated. What help is available for trial and outsourcing managers who need to reduce lab logistics costs?
A: ICON has developed a lab logistics program that not only reduces costs, but guarantees the savings. We can help create a realistic budget based on our extensive experience and your trial needs, negotiate with and manage couriers around the world, and monitor clinical site shipping performance in real time.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel